Moreover, increased expression of TLRs in CD3-CD56+ and CD3+CD56+ cells in GC patients suggests that stimulation of these receptors could contribute to an enhanced immune response to the tumor [14,26,27,28,30]. The gene discussed is NCAM1; the disease is neoplasm.